12/11/15: Puma Biotechnology Breaks News About a Three-Year DFS Follow Up Results—shares halted and reopened multiple times thereafter

NewsHedge Alert: 9:33:13am        Ticker: PBYI

Alert Price: $69.09        Change: – 18.68% within 30-minutes


Catalyst: (news release) Puma Biotechnology (PBYI) said it presented updated results from the phase three clinical trial of PB272, or neratinib, for the extended adjuvant treatment of breast cancer, called the ExteNET trial, in San Antonio, Texas.

The results of the trial demonstrated that treatment with neratinib resulted in a 26% reduction of risk of invasive disease recurrence or death versus placebo. The three-year disease free survival rate for the neratinib arm was 92% and for the placebo arm was 89.9%.


Posted in NewsHedge Alerts and tagged , , , .

Leave a Reply

Your email address will not be published. Required fields are marked *